Unknown

Dataset Information

0

A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG.


ABSTRACT: The only licensed tuberculosis (TB) vaccine, Bacillus Calmette Guerin (BCG), fails to reliably protect adolescents and adults from pulmonary TB, resulting in ~1.6 million deaths annually. Protein subunit vaccines have shown promise against TB in clinical studies. Unfortunately, most subunit vaccines require multiple administrations, which increases the risk of loss to follow-up and necessitates more complex and costly logistics. Given the well-documented adjuvant effect of BCG, we hypothesized that BCG co-administration could compensate for a reduced number of subunit vaccinations. To explore this, we developed an expression-optimized version of our H107 vaccine candidate (H107e), which does not cross-react with BCG. In the CAF®01 adjuvant, a single dose of H107e induced inferior protection compared to three H107e/CAF®01 administrations. However, co-administering a single dose of H107e/CAF®01 with BCG significantly improved protection, which was equal to BCG co-administered with three H107e/CAF®01 doses. Importantly, combining BCG with a single H107e/CAF®01 dose also increased protection in previously BCG-primed animals. Overall, a single dose of H107e/CAF®01 with BCG induced long-lived immunity and triggered BCG-specific Th17 responses. These data support co-administration of BCG and subunit vaccines in both BCG naïve and BCG-primed individuals as an improved TB vaccine strategy with reduced number of vaccination visits.

SUBMITTER: Dijkman K 

PROVIDER: S-EPMC10169149 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG.

Dijkman Karin K   Lindenstrøm Thomas T   Rosenkrands Ida I   Søe Rikke R   Woodworth Joshua S JS   Lindestam Arlehamn Cecilia S CS   Mortensen Rasmus R  

NPJ vaccines 20230509 1


The only licensed tuberculosis (TB) vaccine, Bacillus Calmette Guerin (BCG), fails to reliably protect adolescents and adults from pulmonary TB, resulting in ~1.6 million deaths annually. Protein subunit vaccines have shown promise against TB in clinical studies. Unfortunately, most subunit vaccines require multiple administrations, which increases the risk of loss to follow-up and necessitates more complex and costly logistics. Given the well-documented adjuvant effect of BCG, we hypothesized t  ...[more]

Similar Datasets

| S-EPMC3386939 | biostudies-literature
| S-EPMC10611416 | biostudies-literature
| S-EPMC3023717 | biostudies-literature
2016-05-03 | GSE74282 | GEO
| S-EPMC7260483 | biostudies-literature
| S-EPMC7050365 | biostudies-literature
| S-EPMC4362382 | biostudies-other
| S-EPMC6389677 | biostudies-literature
| S-EPMC7227382 | biostudies-literature
| S-EPMC10923817 | biostudies-literature